Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “RDT’s expeditious move to the highly respected CSE reflects the worldwide interest in the fast-developing medicinal cannabis industry.
“It’s very pleasing to see Sativa’s second investment presenting an initial paper profit for the Company of C$ 0.14 million, a rise of 70 per cent, after only seven months.
“RDT’s technology has very positive implications for both Sativa’s medicinal cannabis business and its CBD-focused 100 per cent subsidiary George Botanicals Limited, and we look forward to continued collaboration with RDT alongside our investment.”
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, announced that shares in its investee business, Rapid Dose Therapeutics Inc., the Toronto-based Pharma-Tech company, are now listed on the Canadian Securities Exchange under the symbol DOSE. RDT’s shares were admitted to the CSE yesterday, Monday 17th December 2018.
Full details of the Company’s investment in RDT are included in its release of 23rd May 2018. At that time, Sativa subscribed for 400,000 RDT shares at C$ 0.50 per share, at a cost of C$ 0.2 million cash. The closing price of RDT’s shares on the CSE yesterday was C$ 0.85.
RDT has its own patent-pending proprietary QuickStrip™ technology, a fast-dissolving strip that is placed on or under the tongue, or inside the cheek, which allows medication to enter directly in to the recipient’s system, mimicking an injection path. Pharmaceuticals, emulsified oils and over-the-counter medicines are used in RDT’s proprietary RDMx mixture technology, which is sold across North America.